Table 3.

Comparison of cerebral SVD in the Meth group versus PS-matched control group after removing the patients with stimulant use for ADHD and cocaine use.

Variables	Meth	PS-matched Control	p
N	48	48
Age	54 ± 10	54 ± 10	0.984
Male (%)	34 (70.8)	39 (81.3)	0.232
Race			0.019
White	37 (77.1)	22 (45.8)
Hispanic	3 (6.3)	3 (6.3)
Black	5 (10.4)	10 (20.8)
Asian	2 (4.2)	8 (16.7)
Other	1 (2.1)	5 (10.4)
Hypertension	31 (64.6)	25 (52.1)	0.214
Diabetes	18 (37.5)	20 (41.7)	0.676
Hyperlipidemia	14 (29.2)	17 (35.4)	0.513
Obesity	9 (18.8)	11 (22.9)	0.615
NIHSS	5 (6)	4 (7)	0.116
Cerebral SVD
WMHs	3 (3)	2 (3)	< 0.001
Lacunes	2 (4)	1 (2)	0.016
Microbleeds	1 (4)	0 (3)	0.445
Enlarged perivascular space	1 (1)	1 (1)	0.206
Total burden	2 (2)	2 (1)	0.009
Baseline SBP	159 ± 31	172 ± 35	0.070
Baseline DBP	90 ± 20	96 ± 20	0.691
SBP at discharge	132 ± 17	133 ± 20	0.838
DBP at discharge	78 ± 13	76 ± 13	0.481
Reduction in SBP	27 ± 25	40 ± 30	0.029
Reduction in DBP	19 ± 20	20 ± 19	0.756
Numbers of Antihypertensives	1 (2)	2 (3)	0.985

The Meth group in this analysis excluded the patients with history of ADHD/stimulant use or cocaine use. Propensity score-matched patients from the Non-Meth group was used as control.

Data are expressed as n (%), mean ± SD, or median (interquartile range, IQR).

DBP diastolic blood pressure, NIHSS National Institutes of Health Stroke Scale, PS propensity score, SBP systolic blood pressure, WMHs white matter hyperdensities.

Significant are in value [bold].